Ridaura (Auranofin) - Summary

RIDAURA SUMMARY

PRESCRIBING INFORMATION
RIDAURA.
Auranofin
Capsules

Ridaura (auranofin) is available in oral form as capsules containing 3 mg auranofin.

Ridaura (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. Ridaura should be added to a comprehensive baseline program, including non-drug therapies.

Unlike anti-inflammatory drugs, Ridaura does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months.

When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active synovitis, particularly in its early stage.

In controlled clinical trials comparing Ridaura with injectable gold, Ridaura was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of Ridaura in patients who are candidates for chrysotherapy.

See all Ridaura indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Ridaura (Auranofin)

Fat Triggers Rheumatoid Arthritis: Discovery Paves Way For New Gene Therapies, Treatments
Source: Arthritis / Rheumatology News From Medical News Today [2013.05.13]
Scientists have discovered that fat cells in the knee secrete a protein linked to arthritis, a finding that paves the way for new gene therapies that could offer relief and mobility to millions worldwide. ar "We found that fat in the knee joints secretes a protein called pro-factor D which gives rise to another protein known as factor D that is linked to arthritis," said Nirmal Banda, Ph.D...

Women Who Smoke May Have Higher Risk for Rheumatoid Arthritis
Source: MedicineNet Rheumatoid Arthritis Specialty [2013.04.29]
Title: Women Who Smoke May Have Higher Risk for Rheumatoid Arthritis
Category: Health News
Created: 4/26/2013 12:35:00 PM
Last Editorial Review: 4/29/2013 12:00:00 AM

Risk For Rheumatoid Arthritis Increased By Smoking
Source: Arthritis / Rheumatology News From Medical News Today [2013.04.23]
Number of cigarettes smoked a day and the number of years a person has smoked both increase the risk of rheumatoid arthritis (RA), finds research in BioMed Central's open access journal Arthritis Research & Therapy. The risk decreases after giving up smoking but, compared to people who have never smoked, this risk is still elevated 15 years after giving up...

Smoking More Than Doubles The Risk Of Rheumatoid Arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2013.04.22]
Smoking just a few cigarettes each day can more than double a woman's risk of rheumatoid arthritis (RA), according to a new study. The research was conducted by scientists from the Karolinska Institutet and Karolinska University Hospital and was published in the journal Arthritis Research & Therapy...

Medications Used To Treat Rheumatoid Arthritis May Affect Abortion Rate In Women
Source: Abortion News From Medical News Today [2013.04.16]
A new study published in the American College of Rheumatology (ACR) journal, Arthritis Care & Research, reveals that women with rheumatoid arthritis (RA) who were on methotrexate (MTX), a drug commonly used to reduce inflammation caused by RA, had lower rates of induced abortions compared to women with RA who were not exposed to the medication...

more news >>

Published Studies Related to Ridaura (Auranofin)

Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years. [1999.05]
BACKGROUND: Sulphasalazine (SSZ) has been reported to cause drug induced systemic lupus erythematosus (SLE), but diagnosis of this complication in the context of rheumatoid arthritis (RA) is difficult. OBJECTIVE: To determine prospectively: (1) if patients become seropositive for antinuclear antibodies (ANA) during prolonged treatment with SSZ without clinical evidence of SLE; (2) if ANA positive patients develop more adverse reactions than ANA negative patients; (3) if drug induced SLE was identified in this cohort... CONCLUSION: ANA positivity is common in patients with RA, but the presence or development of ANA did not increase the likelihood of withdrawing from treatment. No case of drug induced SLE was seen over five years in this study.

A long-term five-year randomized controlled trial of hydroxychloroquine, sodium aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis. [1998.09]
CONCLUSION: Despite the increased popularity of sulphasalazine and inmmunosuppressives, the drugs in this study continue to be used worldwide. The natural history of rheumatoid arthritis requires long-term follow up to establish drug efficacy. Evidence is needed as to whether the newer regimens will prove to be more effective and safer in the longer term than the commonly prescribed DMARDs. The data from this trial will provide a reference for comparison with future studies.

CPH-82 (Reumacon) versus auranofin (Ridaura): a 36-week study of their respective onset of action rates in RA. [1998]
The onset of action rate of CPH-82 (Reumacon), was compared with that of auranofin (AUR; Ridaura) in a 36-week randomised, double-blind, multicentre study of 60 patients with rheumatoid arthritis (RA). As compared with respective baseline values, the CPH-82 group manifested significant improvement in grip strength, Ritchie's articular index (RAI), pain ratings, and HAQ (health assessment questionnaire) scores after 8, 12, 24, and 36 weeks of treatment, with the exception of the 24-week HAQ score...

Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. [1997.08]
The efficacy, toxicity and possible steroid-sparing properties of auranofin in the treatment of elderly-onset rheumatoid arthritis (EORA) were studied in a 2 yr prospective double-blind placebo-controlled clinical trial. Sixty-five patients with onset of arthritis after the age of 60 yr were randomized to either auranofin 3 mg b.i.d...

Sulfasalazine has a better efficacy/toxicity profile than auranofin--evidence from a 5 year prospective, randomized trial. [1996.11]
OBJECTIVE: To compare results of medium to longterm sulfasalazine and auranofin treatment in active rheumatoid arthritis (RA)... CONCLUSION: Sulfasalazine therapy was more likely to be continued for 5 years, suggesting better tolerability and/or efficacy than auranofin, and produced evidence of continuing benefit. Patients previously withdrawn from i.m. gold therapy because of inefficacy or minor toxicity should not be given auranofin therapy.

more studies >>

Clinical Trials Related to Ridaura (Auranofin)

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Recruiting]
This pilot clinical trial studies auranofin in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer. Immunosuppressive therapy, such as auranofin, may be an effective treatment for epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Phase II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) [Recruiting]
The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).

Sirolimus and Auranofin in Treating Patients With Stage IV Non-Small Cell Lung Cancer [Not yet recruiting]
The primary purpose of this study is to find out what effects (good or bad) the drugs auranofin and sirolimus have on patients with lung cancer; to find out if auranofin and sirolimus can stop or slow the growth of the lung cancer; to learn more about how auranafin and sirolimus work against lung cancer by testing blood and tissue samples.

more trials >>